Research
Hormonal
Female patients report greater benefits from GLP-1RA treatment compared to male patients, particularly in mental well-being and physical functioning.
Be aware that female patients may report greater improvements in quality of life and mental well-being from GLP-1RAs than male patients. This is a documented trend in patient experiences.
GoodQualifiesMEDIUM confidence
Gender seems to affect patients’ experiences with the medication, with females reporting more benefits than males
Why this rating
Based on systematic review of multiple studies showing consistent gender trends.
Source
Patients’ experiences with GLP1-RAs – a systematic review
Christoffer Kraul Ibsen et al. · Scandinavian Journal of Primary Health Care · 2025
DOI 10.1080/02813432.2025.2477141
systematic_reviewCited 9×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →